Browsing Tag
Ophthalmology
32 posts
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Why Alcon raised its bid for STAAR Surgical and dropped matching rights in amended merger deal
Find out how Alcon raised its cash bid for STAAR Surgical and removed matching rights to secure a $1.6 billion refractive-technology acquisition.
MeiraGTx signs $475m ophthalmology gene therapy collaboration with Eli Lilly
MeiraGTx Holdings plc signed a USD 475 million gene therapy deal with Eli Lilly and Company to develop AAV-AIPL1 and apply riboswitch tech in ophthalmology.
Belite Bio wins UK MHRA nod to file conditional marketing application for tinlarebant in Stargardt disease
Find out how Belite Bio gained UK MHRA backing to file a conditional marketing application for tinlarebant, advancing the first potential therapy for Stargardt disease.
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Will shareholder pressure derail the STAAR–Alcon merger? Why Yunqi Capital wants the deal scrapped
Yunqi Capital is urging STAAR Surgical to end the Alcon deal delay and explore stronger alternatives—find out why the pressure is mounting now.
Celltrion’s Eydenzelt gets FDA nod — Is Eylea finally facing a real biosimilar rival?
Find out how Celltrion’s FDA-approved Eydenzelt is set to challenge Eylea and reshape the biosimilar landscape for retinal diseases in 2025.
ZEISS gains CE mark for CIRRUS PathFinder AI tool to enhance ophthalmic scan decision support
ZEISS earns CE mark for CIRRUS PathFinder, its integrated AI tool for OCT scan decision support. Find out how it could change ophthalmic diagnostics.
New non-invasive glaucoma therapy makes U.S. debut at Glaucoma Center of San Francisco
First U.S. patient receives Eyetronic nerve stimulation for glaucoma; early data expected 2026 as non-invasive therapy shows promise.
Cloudbreak Pharma’s CBT‑004 Phase 2 success raises hopes for first approved vascularized pinguecula therapy
Cloudbreak Pharma’s CBT‑004 eye drop hit its Phase 2 targets—find out why it could become the first approved vascularized pinguecula therapy by 2028.